EVOK
Evoke Pharma Inc
Halal Rating :
Last Price
$4.40
Last updated:
Market Cap
-
7D Change
5.52%
1 Year Change
519.72%
Company Overview
Industries
Exchange
Next Earnings Date
Evoke Pharma Inc is a specialty pharmaceutical company focused on developing drugs to treat gastrointestinal disorders and diseases. Their main product is GIMOTI® (metoclopramide) nasal spray, which is the first and only FDA-approved nasal spray for relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $2.65m | $4.07m | - | $126027.0 | 0.00% | 3.10% |
| June 30, 2024 | $2.55m | $3.9m | - | $124657.0 | 0.00% | 3.20% |
| March 31, 2024 | $1.74m | $3.36m | - | $124658.0 | 0.00% | 3.71% |
Company Impact
Help us evaluate Evoke Pharma Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.